Cargando…
Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study
BACKGROUND AND RATIONALE: Little is known about SARS-CoV-2 seroconversion in asymptomatic patients affected by solid cancer, and whether it is associated with specific transcriptomics changes in peripheral blood mononuclear cells (PBMC). METHODS: Patients affected by solid cancer treated in a top co...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107211/ https://www.ncbi.nlm.nih.gov/pubmed/35568887 http://dx.doi.org/10.1186/s12967-022-03429-0 |
_version_ | 1784708441873317888 |
---|---|
author | Ravera, Francesco Borea, Roberto Cirmena, Gabriella Dameri, Martina Ferrando, Lorenzo Gallo, Maurizio Casini, Cecilia Fallani, Neri Stabile, Mario Barbero, Valentina Murialdo, Roberto Tixi, Lucia Cappuccio, Margherita Cuboni, Andrea Sivieri, Irene Fornarini, Giuseppe De Maria, Andrea Ballestrero, Alberto Zoppoli, Gabriele |
author_facet | Ravera, Francesco Borea, Roberto Cirmena, Gabriella Dameri, Martina Ferrando, Lorenzo Gallo, Maurizio Casini, Cecilia Fallani, Neri Stabile, Mario Barbero, Valentina Murialdo, Roberto Tixi, Lucia Cappuccio, Margherita Cuboni, Andrea Sivieri, Irene Fornarini, Giuseppe De Maria, Andrea Ballestrero, Alberto Zoppoli, Gabriele |
author_sort | Ravera, Francesco |
collection | PubMed |
description | BACKGROUND AND RATIONALE: Little is known about SARS-CoV-2 seroconversion in asymptomatic patients affected by solid cancer, and whether it is associated with specific transcriptomics changes in peripheral blood mononuclear cells (PBMC). METHODS: Patients affected by solid cancer treated in a top comprehensive cancer center in Italy during the first COVID-19 pandemic wave, and negative for COVID-19-symptoms since the first detection of COVID-19 in Italy, were prospectively evaluated by SARS-CoV-2 serology in the period between April 14th and June 23rd 2020. Follow-up serologies were performed, every 21–28 days, until August 23rd 2020. All SARS-CoV-2 IgM + patients underwent confirmatory nasopharyngeal swab (NPS). PBMCs from a subset of SARS-CoV-2 IgM + patients were collected at baseline, at 2 months, and at 7 months for transcriptome sequencing. RESULTS: SARS-CoV-2 serology was performed on 446 of the 466 recruited patients. A total of 14 patients (3.14%) tested positive for at least one SARS-CoV-2 immunoglobulin in the period between April 14th and August 23rd 2020. Incidence of SARS-CoV-2 IgM decreased from 1.48% in the first month of the accrual to 0% in the last month. Viral RNA could not be detected in any of the NPS. PBMC serial transcriptomic analysis showed progressive downregulation of interleukin 6 upregulated signatures, chemokine-mediated signaling and chemokine-chemokine receptor KEGG pathways. B- and T-cell receptor pathways (p-values = 0.0002 and 0.017 respectively) were progressively upregulated. CONCLUSIONS: SARS-CoV-2 seroconversion rate in asymptomatic patients affected by solid cancer is consistent with that of asymptomatic COVID-19 assessed in the general population through NPS at the peak of the first wave. Transcriptomic features over time in IgM + asymptomatic cases are suggestive of previous viral exposure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03429-0. |
format | Online Article Text |
id | pubmed-9107211 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91072112022-05-16 Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study Ravera, Francesco Borea, Roberto Cirmena, Gabriella Dameri, Martina Ferrando, Lorenzo Gallo, Maurizio Casini, Cecilia Fallani, Neri Stabile, Mario Barbero, Valentina Murialdo, Roberto Tixi, Lucia Cappuccio, Margherita Cuboni, Andrea Sivieri, Irene Fornarini, Giuseppe De Maria, Andrea Ballestrero, Alberto Zoppoli, Gabriele J Transl Med Research BACKGROUND AND RATIONALE: Little is known about SARS-CoV-2 seroconversion in asymptomatic patients affected by solid cancer, and whether it is associated with specific transcriptomics changes in peripheral blood mononuclear cells (PBMC). METHODS: Patients affected by solid cancer treated in a top comprehensive cancer center in Italy during the first COVID-19 pandemic wave, and negative for COVID-19-symptoms since the first detection of COVID-19 in Italy, were prospectively evaluated by SARS-CoV-2 serology in the period between April 14th and June 23rd 2020. Follow-up serologies were performed, every 21–28 days, until August 23rd 2020. All SARS-CoV-2 IgM + patients underwent confirmatory nasopharyngeal swab (NPS). PBMCs from a subset of SARS-CoV-2 IgM + patients were collected at baseline, at 2 months, and at 7 months for transcriptome sequencing. RESULTS: SARS-CoV-2 serology was performed on 446 of the 466 recruited patients. A total of 14 patients (3.14%) tested positive for at least one SARS-CoV-2 immunoglobulin in the period between April 14th and August 23rd 2020. Incidence of SARS-CoV-2 IgM decreased from 1.48% in the first month of the accrual to 0% in the last month. Viral RNA could not be detected in any of the NPS. PBMC serial transcriptomic analysis showed progressive downregulation of interleukin 6 upregulated signatures, chemokine-mediated signaling and chemokine-chemokine receptor KEGG pathways. B- and T-cell receptor pathways (p-values = 0.0002 and 0.017 respectively) were progressively upregulated. CONCLUSIONS: SARS-CoV-2 seroconversion rate in asymptomatic patients affected by solid cancer is consistent with that of asymptomatic COVID-19 assessed in the general population through NPS at the peak of the first wave. Transcriptomic features over time in IgM + asymptomatic cases are suggestive of previous viral exposure. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03429-0. BioMed Central 2022-05-14 /pmc/articles/PMC9107211/ /pubmed/35568887 http://dx.doi.org/10.1186/s12967-022-03429-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Ravera, Francesco Borea, Roberto Cirmena, Gabriella Dameri, Martina Ferrando, Lorenzo Gallo, Maurizio Casini, Cecilia Fallani, Neri Stabile, Mario Barbero, Valentina Murialdo, Roberto Tixi, Lucia Cappuccio, Margherita Cuboni, Andrea Sivieri, Irene Fornarini, Giuseppe De Maria, Andrea Ballestrero, Alberto Zoppoli, Gabriele Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study |
title | Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study |
title_full | Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study |
title_fullStr | Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study |
title_full_unstemmed | Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study |
title_short | Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study |
title_sort | incidence and immunomic features of apyretic covid-19 in patients affected by solid tumors: a prospective cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107211/ https://www.ncbi.nlm.nih.gov/pubmed/35568887 http://dx.doi.org/10.1186/s12967-022-03429-0 |
work_keys_str_mv | AT raverafrancesco incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT borearoberto incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT cirmenagabriella incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT damerimartina incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT ferrandolorenzo incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT gallomaurizio incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT casinicecilia incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT fallanineri incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT stabilemario incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT barberovalentina incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT murialdoroberto incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT tixilucia incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT cappucciomargherita incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT cuboniandrea incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT sivieriirene incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT fornarinigiuseppe incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT demariaandrea incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT ballestreroalberto incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy AT zoppoligabriele incidenceandimmunomicfeaturesofapyreticcovid19inpatientsaffectedbysolidtumorsaprospectivecohortstudy |